 Jenna Burton
Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dog Diseases | 12 | 2024 | 106 | 3.540 |
Why?
| | Cat Diseases | 4 | 2022 | 30 | 1.860 |
Why?
| | Dogs | 14 | 2024 | 478 | 0.930 |
Why?
| | Prednisone | 3 | 2024 | 226 | 0.750 |
Why?
| | Cancer Vaccines | 1 | 2023 | 162 | 0.720 |
Why?
| | Neoplasms | 4 | 2023 | 2913 | 0.700 |
Why?
| | Doxorubicin | 3 | 2024 | 403 | 0.680 |
Why?
| | Cyclophosphamide | 3 | 2024 | 272 | 0.550 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2018 | 35 | 0.540 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2018 | 140 | 0.530 |
Why?
| | Lymphoma, B-Cell | 1 | 2018 | 141 | 0.510 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2018 | 196 | 0.510 |
Why?
| | Mastectomy | 1 | 2018 | 185 | 0.490 |
Why?
| | Cats | 4 | 2022 | 234 | 0.450 |
Why?
| | Ultrasonography | 1 | 2019 | 788 | 0.450 |
Why?
| | Antineoplastic Agents | 4 | 2018 | 2219 | 0.440 |
Why?
| | Veterinary Medicine | 1 | 2014 | 11 | 0.430 |
Why?
| | Osteosarcoma | 3 | 2021 | 89 | 0.370 |
Why?
| | Prostatic Neoplasms | 1 | 2019 | 981 | 0.360 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2011 | 411 | 0.330 |
Why?
| | Adenocarcinoma | 1 | 2018 | 926 | 0.330 |
Why?
| | Soft Tissue Neoplasms | 1 | 2011 | 131 | 0.310 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 1062 | 0.290 |
Why?
| | Animals | 17 | 2024 | 38100 | 0.290 |
Why?
| | Sarcoma | 1 | 2011 | 207 | 0.280 |
Why?
| | Pets | 2 | 2021 | 28 | 0.270 |
Why?
| | Bone Neoplasms | 2 | 2021 | 265 | 0.260 |
Why?
| | Vincristine | 2 | 2024 | 144 | 0.230 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 1969 | 0.190 |
Why?
| | Chlorambucil | 1 | 2022 | 11 | 0.190 |
Why?
| | Gastrointestinal Absorption | 1 | 2022 | 6 | 0.190 |
Why?
| | Lymphoma | 1 | 2024 | 241 | 0.180 |
Why?
| | Area Under Curve | 1 | 2022 | 332 | 0.170 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2022 | 89 | 0.170 |
Why?
| | Administration, Oral | 1 | 2022 | 867 | 0.150 |
Why?
| | Sirolimus | 1 | 2021 | 282 | 0.150 |
Why?
| | Kinetics | 1 | 2022 | 1568 | 0.150 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 735 | 0.150 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2022 | 373 | 0.140 |
Why?
| | Curcumin | 1 | 2018 | 29 | 0.140 |
Why?
| | Liposomes | 1 | 2018 | 263 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 971 | 0.120 |
Why?
| | Liver Neoplasms | 1 | 2022 | 777 | 0.110 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1044 | 0.110 |
Why?
| | Interferon Regulatory Factors | 1 | 2015 | 45 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 241 | 0.110 |
Why?
| | Vaccination | 1 | 2023 | 1428 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2016 | 169 | 0.110 |
Why?
| | Treatment Outcome | 5 | 2024 | 11793 | 0.110 |
Why?
| | Neovascularization, Pathologic | 2 | 2018 | 287 | 0.110 |
Why?
| | Retrospective Studies | 4 | 2024 | 17322 | 0.100 |
Why?
| | Uveitis | 1 | 2015 | 150 | 0.100 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 195 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1450 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2018 | 1150 | 0.080 |
Why?
| | Autoimmune Diseases | 1 | 2015 | 469 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2019 | 1997 | 0.080 |
Why?
| | Immunophenotyping | 1 | 2011 | 322 | 0.080 |
Why?
| | Prospective Studies | 3 | 2024 | 8075 | 0.070 |
Why?
| | Biopsy | 1 | 2011 | 1082 | 0.070 |
Why?
| | Flow Cytometry | 1 | 2011 | 1165 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2028 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2019 | 3915 | 0.060 |
Why?
| | Male | 5 | 2024 | 72992 | 0.060 |
Why?
| | Pilot Projects | 1 | 2011 | 1897 | 0.060 |
Why?
| | Female | 5 | 2024 | 79025 | 0.050 |
Why?
| | Lomustine | 1 | 2024 | 17 | 0.050 |
Why?
| | Asparaginase | 1 | 2024 | 32 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2010 | 923 | 0.050 |
Why?
| | Alanine | 1 | 2024 | 169 | 0.050 |
Why?
| | Purines | 1 | 2024 | 187 | 0.050 |
Why?
| | Absorbable Implants | 1 | 2022 | 38 | 0.050 |
Why?
| | Microspheres | 1 | 2022 | 142 | 0.040 |
Why?
| | Mast Cells | 1 | 2023 | 148 | 0.040 |
Why?
| | Aggression | 1 | 2023 | 180 | 0.040 |
Why?
| | Paclitaxel | 1 | 2022 | 259 | 0.040 |
Why?
| | Therapies, Investigational | 1 | 2021 | 19 | 0.040 |
Why?
| | Carboplatin | 1 | 2021 | 164 | 0.040 |
Why?
| | Cohort Studies | 1 | 2011 | 6032 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2021 | 427 | 0.040 |
Why?
| | PAX5 Transcription Factor | 1 | 2019 | 15 | 0.040 |
Why?
| | Scavenger Receptors, Class A | 1 | 2019 | 13 | 0.040 |
Why?
| | Quality of Life | 1 | 2011 | 3210 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2018 | 91 | 0.030 |
Why?
| | Polymers | 1 | 2022 | 485 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 209 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1270 | 0.030 |
Why?
| | Medical Oncology | 1 | 2021 | 340 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2021 | 456 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2865 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 2094 | 0.030 |
Why?
| | Retinal Neurons | 1 | 2015 | 4 | 0.030 |
Why?
| | Electroretinography | 1 | 2015 | 51 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1723 | 0.030 |
Why?
| | Th17 Cells | 1 | 2015 | 102 | 0.030 |
Why?
| | Gene Deletion | 1 | 2015 | 392 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 961 | 0.030 |
Why?
| | Lymph Nodes | 1 | 2016 | 509 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 420 | 0.020 |
Why?
| | Microglia | 1 | 2015 | 273 | 0.020 |
Why?
| | Retina | 1 | 2015 | 329 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2015 | 507 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 3551 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2016 | 1329 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2015 | 1146 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2015 | 3130 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2069 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 5223 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2933 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 2123 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2015 | 4569 | 0.010 |
Why?
| | United States | 1 | 2021 | 16122 | 0.010 |
Why?
| | Mice | 1 | 2015 | 18357 | 0.010 |
Why?
| | Humans | 1 | 2022 | 145750 | 0.000 |
Why?
|
|
Burton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|